Jazz Pharmaceuticals' (JAZZ) Weak 4Q Results and 2016 Guidance Has Mizuho Securities Sidelined - PT to $124

February 24, 2016 6:54 AM

Mizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $124.00 (from $140.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found